Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.62 |
| ▸ | PKM | P14618 | 1/20 | 0.62 |
| ▸ | UTS2R | Q9UKP6 | 2/20 | 0.55 |
| ▸ | MEN1 | O00255 | 1/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.52 |
| ▸ | TP53 | P04637 | 7/20 | 0.51 |
| ▸ | LMNA | P02545 | 6/20 | 0.51 |
| ▸ | GNRHR | P30968 | 1/20 | 0.47 |
| ▸ | STS | P08842 | 2/20 | 0.47 |
| ▸ | IL1B | P01584 | 1/20 | 0.47 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 2/20 | 0.46 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23675376 | 1.00 | KDM4E (0.62) | KDM4EPKMUTS2RMEN1KMT2A | |
| SCHEMBL23675378 | 0.84 | CNR1 (0.54) | KDM4EMEN1KMT2ALMNASTS | |
| SCHEMBL30100442 | 0.84 | CNR1 (0.54) | KDM4EMEN1KMT2ALMNASTS | |
| SCHEMBL20615733 | 0.84 | KDM4E (0.79) | KDM4EPKMUTS2RMEN1KMT2A | |
| SCHEMBL26098202 | 0.83 | CDK1 (0.49) | UTS2RKMT2AP2RX7 | |
| SCHEMBL30100466 | 0.83 | PKM (0.45) | KDM4EPKMUTS2RMEN1KMT2A | |
| SCHEMBL23675400 | 0.83 | PKM (0.45) | KDM4EPKMUTS2RMEN1KMT2A | |
| SCHEMBL4847812 | 0.82 | CCR2 (0.57) | KDM4EPKMUTS2RMEN1KMT2A | |
| SCHEMBL29268424 | 0.81 | KDM4E (0.62) | KDM4EPKMUTS2RMEN1KMT2A | |
| SCHEMBL23675379 | 0.81 | UTS2R (0.56) | UTS2RTP53LMNAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230140290-A1 | SALICYLAMIDE DERIVATIVES AND RELATED METHODS OF MAKING | THE BOARD OF REGENTS OF THE UNIV OF TEXAS SY (US) | 2023-05-04 | — | — | US | disclosed |
| EP-4093401-A1 | SALICYLAMIDE DERIVATIVES AND RELATED METHODS OF MAKING | The Board of Regents of the University of Texas System (US) | 2022-11-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230140290-A1 | SALICYLAMIDE DERIVATIVES AND RELATED METHODS OF MAKING | EIF2AK2, SARS1, ACE | KDM4E 746/4885PKM 2540/4885UTS2R 2098/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.